Shots:

• Bio-Thera to receive an up front- milestones along with royalties on product sales & will be responsible for the development- manufacturing- supply of BAT1706
• Sandoz to get rights for the commercialization of the therapy upon approval in the US- EU- Canada- and other countries. Bio-Thera’s BAT1706 has completed extensive biosimilar studies- including a global P-III study
• Bevacizumab is a humanized mAb that targets VEGF. Avastin has been approved in the US and EU to treat multiple types of cancer

 Ref: Bio-Thera | Image: Reuters